Skip to main content

Cycloserine Pregnancy and Breastfeeding Warnings

Cycloserine is also known as: Seromycin, Seromycin Pulvules

Medically reviewed by Last updated on Jan 21, 2021.

Cycloserine Pregnancy Warnings

Animal studies given doses up to 100 mg/kg/day have failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is recommended only if clearly needed and the benefit outweighs the risk.

US FDA pregnancy category: C

See references

Cycloserine Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Yes

-This drug many harm a nursing infant.
-This drug is considered compatible with breastfeeding by the American Academy of Pediatrics.
-Some experts state that treatment is not a reason to discontinue breastfeeding, especially in infants older than 2 months.
-Exclusively breastfed infants should be monitored (e.g., drug levels, if toxicity is a concern) if this drug is used during lactation.

Drug levels expressed in milk approached serum drug levels.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Seromycin (cycloserine)." Dura Pharmaceuticals, San Diego, CA.

References for breastfeeding information

  1. "Product Information. Seromycin (cycloserine)." Dura Pharmaceuticals, San Diego, CA.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Briggs GG, Freeman RK. "Drugs in Pregnancy and Lactation. 10th ed." Philadelphia, PA: Wolters Kluwer Health (2015):
  4. National Library of Medicine (US) "Drugs and Lactation Database (LactMed) Available from: URL:" (2006):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.